Risk factor for relapse in pemphigus patients treated with rituximab
의약학 > 피부과학
( Ji Won Kim ) , ( Ji Soo Lim ) , ( Soo Ick Cho ) , ( Jin Ho Chung )
프로그램북(구 초록집) 2017년, 제69권 제2호, 396(총1페이지)
27735701.pdf [무료 PDF 뷰어 다운로드]
  • ※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
  • 구매가격
    30원 (구매자료 3% 적립)
    이메일 발송  스크랩 하기
    자료 다운로드  네이버 로그인
    Background: Many studies reported the outcome of rituximab use in pemphigus, but studies on clinical risk factors affecting clinical outcome or relapse are insufficient.
    Objectives: The purpose of this study was to find out the clinical outcome and risk factor of relapse in patients diagnosed with pemphigus and treated with rituximab.
    Methods: A retrospective chart analysis was performed on pemphigus patients who were treated with rituximab in the dermatology clinic of Seoul National University Hospital.
    Results: A total of 40 patients with pemphigus were treated with rituximab, of which 39 had remission. Twenty-seven patients were treated with less than 2 infusions, while 13 patients were treated with more than 3 infusions. Among them, 24 patients showed complete remission, 15 patients showed partial remission, and 1 patient died during treatment. The most important clinical factor affecting remission and recurrence was the presence of mucosal lesions. The risk of relapse was 4.2 times higher in patients with mucosal lesions than in those without (p= 0.039). There was no statistically significant difference in sex, age, type of pemphigus, number of rituximab infusion (less than 2 or more than 3 infusions), disease duration, and severity score.
    Conclusion: In pemphigus patients treated with rituximab, presence of mucosal lesions resulted in poor clinical outcome and frequent recurrence. Therefore, pemphigus patients with mucosal lesions should consider more aggressive treatment.
    사업자등록번호 220-87-87785 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.070-8809-9397
    개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1765호 이메일 help@reportshop.co.kr
    copyright (c) 2009 happynlife. steel All reserved.